In this episode, Vera spoke with Dr. Sam Lee, Co-Chief Executive Officer and President of Cocrystal Pharma, a clinical-stage biotech company focusing on antiviral drug development with a unique structure-based drug discovery platform.

With over 25 years of experience in anti-infective drug discovery, Dr. Lee brings a wealth of knowledge to the discussion on the urgent need for innovative antiviral therapies.

The conversation begins with Dr. Lee sharing insights on the mission of Cocrystal Pharma, which leverages Nobel Prize-winning expertise in the development of antiviral drugs.

Vera and Dr. Lee then discuss the recent emergence of a new strain of Avian flu, examining the potential risks and the current state of flu vaccines in providing protection against both seasonal and pandemic strains.

Dr. Lee delves into the challenges of pandemic preparedness and explains how broad-spectrum antivirals could offer a valuable tool in combating influenza outbreaks. He provides an overview of Cocrystal Pharma’s approach, particularly their focus on targeting viral replication proteins, which sets their platform apart from traditional antiviral discovery methods.

The discussion also covers the limitations of current antiviral treatments and highlights the unmet medical needs in influenza care.

As the conversation wraps up, Dr. Lee discusses his excitement for the future of antiviral drug development.

Tune in to gain an understanding of the evolving landscape of antiviral research and the cutting-edge innovations that could redefine treatment options for viral infections.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Twitter: https://twitter.com/Xtalks